Adisord® (Adisord®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceNifuroxazideNifuroxazide
Similar drugsTo uncover
  • Adisord®
    capsules inwards 
    Bakter, OOO     Russia
  • Adisord®
    suspension inwards 
    Bakter, OOO     Russia
  • Mirofuril
    capsules inwards 
    OBNINSKAYA CHEMICAL - PHARMACEUTICAL COMPANY, CJSC     Russia
  • Mirofuril
    suspension inwards 
    OBNINSKAYA CHEMICAL - PHARMACEUTICAL COMPANY, CJSC     Russia
  • Nyfural®
    capsules inwards 
    OBOLENSKOE PHARMACEUTICAL ENTERPRISE, CJSC     Russia
  • Nifuroxazide
    capsules inwards 
    VERTEKS, AO     Russia
  • Nifuroxazide
    capsules inwards 
    ATOLL, LLC     Russia
  • Nifuroxazide
    suspension inwards 
    ECOLAB, CJSC     Russia
  • Stoppier
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Stoppier
    suspension inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Stoppier
    capsules inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Ecofuryl®
    capsules inwards 
    AVVA RUS, OJSC     Russia
  • Ecofuryl®
    suspension inwards 
    AVVA RUS, OJSC     Russia
  • Elufor
    suspension inwards 
    ATOLL, LLC     Russia
  • Elufor
    capsules inwards 
    ATOLL, LLC     Russia
  • Enterofuryl®
    suspension inwards 
    Boznalek, AO     Bosnia and Herzegovina
  • Enterofuryl®
    capsules inwards 
    Boznalek, AO     Bosnia and Herzegovina
  • Ersefuril®
    capsules inwards 
    Sanofi-Aventis France     France
    • Dosage form: & nbspcapsules
    Composition:

    Dosage of 100 mg

    1 capsule contains:

    active substance: nifuroxazide 100 mg;

    Excipients: calcium hydrophosphate dihydrate 25 mg, corn starch pregelatinized starch 33 mg, mannitol 20 mg, magnesium stearate 1 mg, talc 1 mg;

    hard gelatin capsule №2:

    housing - titanium dioxide 0.3811 mg, gelatin 37.3478 mg, iron oxide dye yellow 0.3811 mg.

    cap - titanium dioxide 0.2289 mg, gelatin 22.4322 mg, iron oxide dye yellow 0.2289 mg.

    Dosage 200 mg

    1 capsule contains:

    active substance: nifuroxazide 200 mg;

    Excipients: calcium hydrophosphate dihydrate 50 mg, corn starch pregelatinized 66 mg, mannitol 40 mg, magnesium stearate 2 mg, talc 2 mg;

    hard gelatin capsule №0:

    housing - titanium dioxide 0.7867 mg, gelatin 57.6681 mg, dye quinoline yellow 0.5426 mg, dye sunset yellow 0.0026 mg.

    cap - titanium dioxide 0.4933 mg, gelatin 36.1648 mg, quinoline yellow dye 0.3403 mg, dye sunset yellow 0.0016 mg.
    Description:

    Hard gelatin capsules:

    - No. 2: body and cap of dark yellow color (dosage 100 mg);

    - No. 0: body and lid yellow (200 mg dosage).

    The contents of the capsules are a mixture of granules and yellow powder. Inclusions of the compressed mass of yellow color, scattered when pressed lightly, are allowed.

    Pharmacotherapeutic group:Antimicrobial agent, nitrofuran
    ATX: & nbsp

    A.07.A.X.03   Nifuroxazide

    Pharmacodynamics:

    Nifuroxazide is a derivative of nitrofuran, antimicrobial action against Gram-positive Staphylococcus spp., and some gram-negative microorganisms: Yersinia spp., Escherichia spp., Citrobacter spp., Enterobacter spp., Salmonella spp. Nifuroxazide does not have an antimicrobial effect on Proteus vulgaris, Klebsiella spp., Proteus mirabilis and Pseudomonas aeruginosa. Presumably blocks the activity of dehydrogenases and depresses respiratory chains, a cycle of tricarboxylic acids and a number of other biochemical processes in a microbial cell. Does not disturb the balance of the intestinal microflora. With acute bacterial diarrhea, eubiosis of the intestine is restored. When infected with enterotrophic viruses prevents the development of bacterial superinfection.

    Pharmacokinetics:

    After oral administration nifuroxazide practically not absorbed from the gastrointestinal tract and does not have a systemic effect; 99% the accepted dose remains in the intestine and has its own antimicrobial effect there. It is excreted by the intestine.

    Indications:Diarrhea of ​​bacterial genesis without signs of helminthic invasion.
    Contraindications:

    - hypersensitivity to nifuroxazide, nitrofuran derivatives or any excipients of the drug

    - children under 3 years.

    Pregnancy and lactation:

    Preclinical studies showed no risk to the fetus, but there are no controlled studies in pregnant women.

    The potential risk to humans is unknown. Breastfeeding is possible with short-term therapy. In pregnancy and during breastfeeding apply only if the intended benefit to the mother exceeds the potential risk to the fetus and the baby. It is necessary to consult a doctor.

    Dosing and Administration:

    It is applied inside. Capsule should be swallowed whole, washed down with a small amount of water.

    Adults and children older than 6 years: 2 capsules of 100 mg or 1 capsule of 200 mg 4 times daily (800 mg / day).

    Children from 3 to 6 years: 2 capsules of 100 mg or 1 capsule of 200 mg 3 times a day (600 mg / day).

    The duration of the course of treatment is 5-7 days, but not more than 7 days. If there is no improvement within the first 3 days, you should consult a doctor.

    Side effects:

    Disorders from the immune system: allergic reactions (skin rash, hives, Quincke's edema, shortness of breath, anaphylactic shock).General disorders and disorders at the site of administration: abdominal pain, nausea, diarrhea, granulocytopenia.

    If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

    Overdose:

    Symptoms of overdose are not described. In case of an overdose, gastric lavage and symptomatic treatment are recommended.

    Interaction:

    With the simultaneous administration of ethanol, a disulfiram-like reaction may develop (abdominal pain, nausea, vomiting, headache, tachycardia, blurred vision, weakness, convulsions). It is not recommended simultaneous use with drugs that depress the central nervous system.

    Special instructions:

    If necessary, rehydration should be carried out. The volume of the injected liquid and the way it is administered (parenterally, intravenously) should correspond to the degree of diarrhea, age and clinical condition of the patient.

    In the case of bacterial diarrhea with signs of systemic damage (worsening of the general condition, fever,symptoms of intoxication or infection) should consult a doctor about deciding whether to use antimicrobials of systemic action.

    During therapy with nifuroxazide, alcohol is prohibited.

    When symptoms of an allergic reaction appear (including shortness of breath, skin rash, itching), stop taking the drug.

    Effect on the ability to drive transp. cf. and fur:

    The drug Adisord® does not affect the ability to drive vehicles or engage in other potentially hazardous activities.

    Form release / dosage:Capsules 100 mg and 200 mg.
    Packaging:

    By 7, 10 or 15 capsules in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    For 2, 3, 4 contour packs of 7, 10 or 15 capsules together with the instructions for use are placed in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-003121
    Date of registration:30.07.2015/ 23.09.2016
    Expiration Date:30.07.2020
    The owner of the registration certificate:Bakter, OOOBakter, OOO Russia
    Manufacturer: & nbsp
    Representation: & nbspCANONFARMA PRODUCTION CJSC CANONFARMA PRODUCTION CJSC Russia
    Information update date: & nbsp04.02.2017
    Illustrated instructions
      Instructions
      Up